Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

Martina Penazzato; Claire L Townsend; Natella Rakhmanina; Yao Cheng; Moherndran Archary; Tim R Cressey; Maria H Kim; Victor Musiime; Anna Turkova; Theodore D Ruel; Helena Rabie; Nandita Sugandhi; Pablo Rojo; Meg Doherty; Elaine J Abrams; PADO4 participants

doi:10.1016/S2352-3018(19)30193-6

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

Lancet HIV. 2019 Sep;6(9):e623-e631. doi: 10.1016/S2352-3018(19)30193-6.

Authors

Collaborators

PADO4 participants:
Elaine Abrams, Jintanat Ananworanich, Isabelle Andrieux-Meyer, Moherndran Archary, Yodit Belew, Brookie Best, Rosa Bologna, Jessica Burry, Deborah Carpenter, Yao Cheng, Polly Clayden, Angela Colbers, Magda Conway, Timothy R Cressey, Mutsa Dangarembizi, Shaffiq Essajee, Maribel Gonzalez Tome, Andrew Hill, Saye Khoo, Maria Kim, Linda Lewis, Janice Lee, Shahin Lockman, Imelda Mahaka, Mark H Mirochnick, Lynne Mofenson, Mireille Muhimpundu, Angela Mushavi, Victor Musiime, Elizabeth Obimbo, Fernando Pascual, Carmen Perez Casas, Anton Pozniak, Helena Rabie, Natella Rakhmanina, Pablo Rojo, Theodore Ruel, Jonathan Schapiro, George Siberry, Teresa Beatriz Simione, Nandita Sugandhi, Cheick Tidiane Tall, Anna Turkova, Francois Venter, Marissa Vicari, Jenny Walsh, Jacque Wambui, Melynda Watkins

Affiliations

¹ HIV Department, World Health Organization, Geneva, Switzerland. Electronic address: [email protected].
² HIV Department, World Health Organization, Geneva, Switzerland.
³ The George Washington University, School of Medicine & Health Sciences, Washington, DC, USA; Children's National Medical Center, Washington, DC, USA; Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.
⁴ Medicines Patent Pool, Geneva, Switzerland.
⁵ Department of Paediatrics, University of KwaZulu-Natal, Durban, South Africa.
⁶ Program for HIV Prevention and Treatment - Institut de Recherche pour le Développement, Unit 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
⁷ Department of Pediatrics, Baylor International Pediatric AIDS Initiative, Baylor College of Medicine, Houston, TX, USA; Baylor College of Medicine Abbott Fund Children's Clinical Centre of Excellence Malawi, Lilongwe, Malawi.
⁸ Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda; Research Department, Joint Clinical Research Centre, Kampala, Uganda.
⁹ Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, UK.
¹⁰ Division of Pediatric Infectious Diseases and Global Health, University of California, San Francisco, CA, USA.
¹¹ Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
¹² ICAP at Columbia University, New York, NY, USA.
¹³ Pediatric Infectious Diseases Unit, Pediatric Department, Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.
¹⁴ ICAP at Columbia University, New York, NY, USA; Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.

PMID: 31498110
DOI: 10.1016/S2352-3018(19)30193-6

Abstract

Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.

Publication types

Review

MeSH terms

Adolescent
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / therapeutic use*
Child
Congresses as Topic
Developing Countries
Drug Compounding / trends
Female
HIV Infections / drug therapy*
Humans
Infant
Infant, Newborn
Lactation
Pregnancy

Substances

Anti-HIV Agents

Grants and funding

001/WHO_/World Health Organization/International